Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/33149
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWiendl, H.-
dc.contributor.authorComi, G.-
dc.contributor.authorOreja-Guevara, C.-
dc.contributor.authorSiva, A.-
dc.contributor.authorVAN WIJMEERSCH, Bart-
dc.contributor.authorWuerfel, J.-
dc.contributor.authorBuffels, R.-
dc.contributor.authorKadner, K.-
dc.contributor.authorKuenzel, T.-
dc.contributor.authorVermersch, P.-
dc.date.accessioned2021-01-22T14:33:26Z-
dc.date.available2021-01-22T14:33:26Z-
dc.date.issued2020-
dc.date.submitted2021-01-21T09:28:09Z-
dc.identifier.citationMultiple Sclerosis Journal, 26 (3_SUPPL) , p. 224 -225-
dc.identifier.urihttp://hdl.handle.net/1942/33149-
dc.language.isoen-
dc.publisherSAGE PUBLICATIONS LTD-
dc.titleOcrelizumab phase iiib efficacy from casting: 2-year neda (mri re-baselined) subgroup rates in rrms patients with a suboptimal response to prior dmts-
dc.typeJournal Contribution-
local.bibliographicCitation.conferencedateSEP 11-13, 2020-
local.bibliographicCitation.conferencename8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual)-
local.bibliographicCitation.conferenceplaceELECTR NETWORK-
dc.identifier.epage225-
dc.identifier.issue3_SUPPL-
dc.identifier.spage224-
dc.identifier.volume26-
local.format.pages2-
local.bibliographicCitation.jcatM-
local.publisher.place1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND-
local.type.refereedRefereed-
local.type.specifiedMeeting Abstract-
dc.identifier.isiWOS:000596547100445-
local.provider.typewosris-
local.uhasselt.uhpubyes-
local.description.affiliation[Wiendl, H.] Univ Munster, Munster, Germany.-
local.description.affiliation[Comi, G.] Univ Vita Salute San Raffaele, Milan, Italy.-
local.description.affiliation[Oreja-Guevara, C.] Hosp Clin San Carlos, Madrid, Spain.-
local.description.affiliation[Siva, A.] Istanbul Univ, Cerrahpasa Sch Med, Istanbul, Turkey.-
local.description.affiliation[Van Wijmeersch, B.] Hasselt Univ, Pelt, Belgium.-
local.description.affiliation[Van Wijmeersch, B.] Rehabil & MS Ctr Pelt, Pelt, Belgium.-
local.description.affiliation[Wuerfel, J.] Univ Basel, Med Image Anal Ctr MIAC AG, Basel, Switzerland.-
local.description.affiliation[Wuerfel, J.] Univ Basel, Dept Biomed Engn, Basel, Switzerland.-
local.description.affiliation[Buffels, R.; Kadner, K.; Kuenzel, T.] F Hoffmann La Roche Ltd, Basel, Switzerland.-
local.description.affiliation[Vermersch, P.] Univ Lille, Lille, France.-
local.uhasselt.internationalyes-
item.fulltextNo Fulltext-
item.contributorWiendl, H.-
item.contributorComi, G.-
item.contributorOreja-Guevara, C.-
item.contributorSiva, A.-
item.contributorVAN WIJMEERSCH, Bart-
item.contributorWuerfel, J.-
item.contributorBuffels, R.-
item.contributorKadner, K.-
item.contributorKuenzel, T.-
item.contributorVermersch, P.-
item.fullcitationWiendl, H.; Comi, G.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Wuerfel, J.; Buffels, R.; Kadner, K.; Kuenzel, T. & Vermersch, P. (2020) Ocrelizumab phase iiib efficacy from casting: 2-year neda (mri re-baselined) subgroup rates in rrms patients with a suboptimal response to prior dmts. In: Multiple Sclerosis Journal, 26 (3_SUPPL) , p. 224 -225.-
item.accessRightsClosed Access-
crisitem.journal.issn1352-4585-
crisitem.journal.eissn1477-0970-
Appears in Collections:Research publications
Show simple item record

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.